Estephan Zayat, MD
Gastroenterology · Wichita, KSNPI 1558361261
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,770 of the $9,508 with a category attached, or 71.2%. 33 manufacturers reported payments, led by Echosens North America, Inc. at 27.3% of the total. Reporting peaked in 2019 at $3,588 and has fallen 70.3% since, to $1,064 in 2025.
Across 263 payments — averaging $36.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Echosens North America, Inc.$3K
- AbbVie$1K
- Johnson & Johnson$877
- Boston Scientific$495
- Gilead$492
- Janssen Scientific Affairs, LLC$470
- plus $3K from 27 others
Across 24 payments — averaging $4401.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$65K
- Regeneron$26K
- Eli Lilly$11K
- AbbVie$5K
What the payments were for
- Travel & lodging$2,59627%
- Food & beverage$6,77071%
- Education$1421%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Echosens North America, Inc. | 2 | $2,596 |
| AbbVie(2 entities) | 53 | $1,316 |
| Johnson & Johnson(2 entities) | 67 | $877 |
| Boston Scientific | 4 | $495 |
| Gilead | 10 | $492 |
| Janssen Scientific Affairs, LLC | 4 | $470 |
| Medtronic(2 entities) | 7 | $406 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $365 |
| Pfizer | 17 | $315 |
| Intercept Pharmaceuticals, Inc. | 8 | $302 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $221 |
| Ipsen Biopharmaceuticals, Inc | 2 | $166 |
| Lilly USA, LLC | 3 | $165 |
| Regeneron Healthcare Solutions, Inc. | 9 | $151 |
| Mallinckrodt Hospital Products Inc. | 2 | $148 |
| Phathom Pharmaceuticals, Inc. | 3 | $145 |
| Celltrion USA Inc. | 7 | $123 |
| UCB, Inc. | 4 | $104 |
| GSK | 1 | $104 |
| Intuitive Surgical | 1 | $90 |
| Sanofi | 4 | $82 |
| Ironwood Pharmaceuticals, Inc | 5 | $69 |
| Ardelyx, Inc. | 4 | $64 |
| Alnylam Pharmaceuticals Inc. | 2 | $43 |
| Aimmune Therapeutics, Inc. | 2 | $38 |
| Bristol Myers Squibb | 2 | $28 |
| Braintree Laboratories, Inc. | 2 | $25 |
| Fresenius Kabi USA, LLC | 1 | $23 |
| Madrigal Pharmaceuticals | 1 | $22 |
| Micro-tech Endoscopy USA, Inc. | 1 | $20 |
| Organon | 1 | $16 |
| QOL Medical, LLC | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,508 in reported general payments places this provider in the 85th percentile of 98 gastroenterology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 50 | $1,388,221 |
| Dupixent PenDupilumab | 14 | $104,143 |
| LinzessLinaclotide | 64 | $53,250 |
| XifaxanRifaximin | 14 | $43,159 |
| TrulancePlecanatide | 20 | $18,623 |
| ZenpepLipase/Protease/Amylase | 14 | $18,598 |
| Mesalamine | 61 | $17,401 |
| MovantikNaloxegol Oxalate | 27 | $11,751 |
| Mesalamine ErMesalamine | 42 | $8,836 |
| Dexlansoprazole DrDexlansoprazole | 22 | $6,719 |
| Budesonide DrBudesonide | 40 | $5,167 |
| Pantoprazole Sodium | 305 | $3,126 |
| Colestipol Hcl | 38 | $2,651 |
| Lubiprostone | 12 | $2,409 |
| Ursodiol | 27 | $2,203 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $877 | $1,388,22150 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $221 | $61,78234 claims |
| AbbVieLinzess | $1,316 | $53,25064 claims |
| Aimmune Therapeutics, Inc.Zenpep | $38 | $18,59814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 98 gastroenterology providers in Kansas.
Other gastroenterology in Wichita
- Mark BowlesWichita$11K
- Maria ChangWichita$6K
- Winnie Sheu WocWichita$6K
- William KilgoreWichita$5K
- Obada TayyemWichita$5K
- Saritha GorantlaWichita$3K
- Gebran KhneizerWichita$3K
- Bassem MattaWichita$3K
- Michael LievensWichita$1K
- Natalie FarhaWichita$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.